As a leading manufacturer of generics, we offer a wide range of INN and branded generics, specialty products, and consumer healthcare solutions.

Our two R&D centers, located in Prague and Ankleshwar, completed over 100 product submissions in 2024. The team actively manages the lifecycle of active pharmaceutical ingredients, enabling us to launch products immediately after the loss of exclusivity while driving innovation in drug formulation, with a focus on bioequivalent and value-added medicines, and green design solutions.

Our Development team reached a milestone with the introduction of Zentiva’s first Value-Added Medicine (VAM) ever.

Dasatinib registered in UK and EU countries is a life-saving oncology treatment which delivers the active ingredient irrespectively of the acidity in the stomach altered by natural conditions or concomitant medications. Dasatinib is used to treat people with chronic myeloid leukaemia and people with acute lymphoblastic leukaemia who are positive for the Philadelphia chromosome.

The internal capability of our team is augmented by a network of academic partnerships including the flagship ‘The Parc’ programme and the ‘Open Innovation Programme’.

About The Parc

Zentiva is a founding member of The Parc (The Pharmaceutical Applied Research Center), a pharmaceutical research platform offering a postgraduate programme that is based on collaboration between academic and industrial partners. It allows to solve real problems directly connected to some of today’s major challenges and implement results into real products! By the end of 2024, seven years after The PARC’s inception, 33 students are currently enrolled, and 55 have successfully completed the programme.

About our Open Innovation Programme

Our experts continue to explore new ways to improve current pharmaceutical products, simplify administration, increase patient compliance and keep healthcare accessible to everybody.

Innovation means collaboration and we would like to join forces with those who are having the same commitment and asking the same questions than we do.

With our open innovation programme we can make the difference together.